T900607 in Treating Patients With Gastroesophageal Junction Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00054249|
Recruitment Status : Completed
First Posted : February 6, 2003
Last Update Posted : July 18, 2013
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
|Condition or disease||Intervention/treatment||Phase|
|Gastric Cancer||Drug: T900607||Phase 2|
- Determine the response rate (complete and partial) in patients with previously treated gastric or gastroesophageal junction carcinoma treated with T900607. (Gastric carcinoma closed to accrual as of 02/04.)
- Determine the duration of response and time to disease progression in patients treated with this drug.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the safety profile of this drug in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive T900607 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study Of Intravenous T900607-Sodium In Subjects With Previously Treated Gastric Carcinoma|
|Study Start Date :||September 2002|
|Primary Completion Date :||October 2004|
|Study Completion Date :||September 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00054249
|United States, Ohio|
|Ireland Cancer Center|
|Cleveland, Ohio, United States, 44106-1714|
|Study Chair:||Joanna M. Brell, MD||Case Comprehensive Cancer Center|